The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000618358
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
26/03/2026
Date registered
Help: Date registered
20/05/2026
Date last updated
Help: Date last updated
20/05/2026
Date data sharing statement initially provided
Help: Data sharing statement date
20/05/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Effectiveness of a lifestyle intervention on cognitive decline in people with mild cognitive problems:The CogCoach-Brain trial
Scientific title
Effectiveness of the CogCoach-Brain multidomain lifestyle intervention on cognitive decline in adults aged 60 years and older with subjective cognitive decline and mild cognitive impairment
Additional trial identifiers [1] 316453 0
Nil
Universal Trial Number (UTN)
Trial acronym
CogCoach-Brain
Related trial records

Health condition
Health condition(s) studied:
Subjective Cognitive Decline 340566 0
Mild Cognitive Impairment 341736 0
Condition category
Condition code
Neurological 336766 336766 0 0
Dementias
Public Health 336875 336875 0 0
Other public health
Neurological 336876 336876 0 0
Alzheimer's disease
Public Health 337808 337808 0 0
Health promotion/education

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
The CogCoach Brain Online Intervention Includes the follow
E-learning:

Participants will complete a 12-week online education program focused on reducing dementia risk. The e-learning component includes six self-paced online modules ("Chapters"), each taking approximately 30–40 minutes to complete.
The modules cover the following topics:
1. Introduction to the course and healthy brain ageing
2. Looking After Your Memory
3. Physical Activity
4. Healthy Diet
5. Staying Cognitively and Socially Active
6. Stress Reduction

Each module provides background information on the topic, along with interactive activities, reflection prompts, and goal-setting exercises to support behaviour change. Interactive activities include things such as quizzes to test knowledge, reflective exercises, goal-setting tasks (e.g., setting weekly goals). Intervention participants will receive access to these modules during Weeks 1, 2, 4, 6, 8, and 10 of the programs.

Telehealth Consultations

a) Cognitive Engagement Consultation:
One session on cognitive engagement will be delivered by a research assistant with at least four years of psychology training. Sessions will be conducted individually via videoconferencing or, where not possible, by phone, and will last up to one hour. This consultation will occur in Week 1 or as soon as possible after randomisation. It includes discussion and planning of a Cognitive Diary and goal setting related to cognitively stimulating activities. Participants will also receive guidance on using BrainHQ for cognitive training. They will be given a 12-month BrainHQ subscription at the beginning of the intervention and will be encouraged to complete two executive-function tasks and two memory tasks per week (up to two hours of training) for up to 2 hours per week. Example executive function training tasks include the Double Decision task, participants are shown a car briefly at the centre of the screen and a road sign in the periphery. After the display disappears, they are shown two car options and are required to identify which car was presented, as well as indicate the location of the road sign. In the Juggle Factor task, participants are presented with a sequence of numbers that are placed within moving circles; they are required to reconstruct the sequence in the correct order and in the correct locations.
An example Memory training task is Memory Grid in which participants are shown a grid of cards with associated sounds and are required to click on cards and match pairs by remembering their locations and sounds.

b) Physical Activity Consultations
Two consultations on physical activity will be delivered by an accredited exercise physiologist (EP). Each session will be conducted individually via videoconferencing or, where not possible, by phone, and will last up to 45 minutes. Sessions will occur approximately in Weeks 5 and 9.
The first session involves development of a personalised exercise plan based on the Australian physical activity guidelines. The second session focuses on reviewing progress, supporting goal attainment, and troubleshooting barriers. Where appropriate, the EP will introduce Physitrack or the StandingTall app to support ongoing physical activity. These apps provide guided digital exercise programs delivered via a tablet or mobile device, with instructions, cues, and difficulty levels adapted to the participant’s needs. Participants may use their own device or one supplied by the study.

c) Dietary Consultations
Two consultations on diet will be delivered by a qualified dietitian. Sessions will be conducted individually via videoconferencing or, where not possible, by phone, and will last up to 1 hour each. They will occur approximately in Weeks 7 and 11.
The first session focuses on developing an individualised dietary plan and setting goals based on the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet. The MIND diet emphasises consumption of unprocessed fruit and vegetables, whole grains, nuts, olive oil, fish, legumes, and low consumption of red meat. Dietary adaptations will be made to ensure cultural suitability.
The second session involves reviewing progress and adjusting strategies to support participants in achieving their dietary goals.


Telehealth Booster Sessions
Telehealth booster sessions will be conducted at approximately 4 months, 9 months and again at approximately 18 months following completion of the e-learning program. These sessions will be delivered via videoconference wherever possible, or by phone as an alternative, and will last approximately 45 minutes each. Booster sessions will follow a standardised template based on motivational interviewing principles, focusing on reviewing goals, discussing progress, addressing challenges, and supporting continued behaviour change. Each session will also include a brief recap of key intervention materials.

Adherence:
Adherence to the e-learning components will be monitored using website analytics (e.g., time spent on each chapter, number of chapters completed, number of interactive activities completed). We will also record whether participants choose not to attend consultations or engage in cognitive training. To encourage adherence, reminder emails will be sent to participants who have not completed a chapter. Access to subsequent chapters will not be restricted based on completion of earlier modules.

Process Evaluation
Process evaluation will be embedded within the e-learning modules through questions assessing participants’ familiarity with the topics, willingness to change behaviour, and perceptions of health. Across the modules and booster sessions, we will also collect information on goals set by participants and their general feedback on the program.

Biomarker Collection
A subsample of participants from both the intervention and active control groups will be invited to take part in an optional biomarker collection. Consenting participants will provide blood samples at baseline and again at 24 months post intervention. The biomarkers to be assessed at baseline and 24 months post intervention include measures of proteins associated with Alzheimer's disease (plasma Aß42/40, p-tau217), markers of neurodegeneration (neurofilament light), astrogliosis (GFAP), and general inflammation (c-reactive protein). Participation in this component is voluntary and does not affect involvement in the main trial. In addition, APOE4 genotype will be obtained from the baseline data collection but is not a trial outcome measure.


Intervention code [1] 333113 0
Prevention
Intervention code [2] 333116 0
Behaviour
Intervention code [3] 333117 0
Lifestyle
Description of the comparator or control
Participants allocated to the Health Education active control group will also complete a 12-week online education program focused on reducing dementia risk. The e-learning component includes six self-paced online modules ("Chapters"), each taking approximately 30–40 minutes to complete and will be scheduled as the intervention timepoint.

The active control group will not receive cognitive engagement, exercise physiology and diet consultations, access to computerised brain training, the exercise app nor booster sessions.

Control group
Active

Outcomes
Primary outcome [1] 344285 0
Cognitive function
Timepoint [1] 344285 0
Baseline, 6 months Post Intervention (12 weeks), 12 months and 24 months Post Intervention (primary endpoint).
Secondary outcome [1] 457330 0
Level of exposure to dementia risk factors
Timepoint [1] 457330 0
Baseline, Immediately Post Intervention (12 weeks), 6 months Post Intervention, 12 months and 24 months Post Intervention
Secondary outcome [2] 457331 0
Level of physical activity
Timepoint [2] 457331 0
Baseline, Immediately Post Intervention (12 weeks), 6 months Post Intervention, 12 months and 24 months Post Intervention
Secondary outcome [3] 457332 0
Adherence to the Mediterranean-DASH intervention for Neurodegenerative Delay (MIND) Diet
Timepoint [3] 457332 0
Baseline; immediately post-intervention (12 weeks); 6 months post-intervention; 12 months post-intervention; 24 months post-intervention
Secondary outcome [4] 457333 0
Cognitive engagement
Timepoint [4] 457333 0
Baseline, Immediately Post Intervention (12 weeks), 6 months Post Intervention, 12 months and 24 months Post Intervention
Secondary outcome [5] 457334 0
Health-related quality of Life
Timepoint [5] 457334 0
Baseline, Immediately Post Intervention (12 weeks), 6 months Post Intervention, 12 months and 24 months Post Intervention
Secondary outcome [6] 457336 0
Weekly Step count
Timepoint [6] 457336 0
Baseline, Immediately Post Intervention (12 weeks), 6 months Post Intervention, 12 months and 24 months Post Intervention
Secondary outcome [7] 457337 0
Quality of life
Timepoint [7] 457337 0
Baseline, Immediately Post Intervention (12 weeks), 6 months Post Intervention, 12 months and 24 months Post Intervention
Secondary outcome [8] 457338 0
Dementia literacy
Timepoint [8] 457338 0
Baseline, Immediately Post Intervention (12 weeks), 6 months Post Intervention, 12 months and 24 months Post Intervention
Secondary outcome [9] 461122 0
Executive function
Timepoint [9] 461122 0
Baseline; immediately post-intervention (12 weeks); 6 months post-intervention; 12 months post-intervention; and 24 months post-intervention.
Secondary outcome [10] 461123 0
Memory
Timepoint [10] 461123 0
Baseline; immediately post-intervention (12 weeks); 6 months post-intervention; 12 months post-intervention; and 24 months post-intervention.
Secondary outcome [11] 461124 0
Processing speed
Timepoint [11] 461124 0
Baseline; immediately post-intervention (12 weeks); 6 months post-intervention; 12 months post-intervention; and 24 months post-intervention.
Secondary outcome [12] 461418 0
Level of tau protein in plasma (ptau 217)
Timepoint [12] 461418 0
Baseline, 24 months post intervention
Secondary outcome [13] 461419 0
Level of amyloid proteins in plasma (Abeta 42/40)
Timepoint [13] 461419 0
Baseline, 24 months post intervention
Secondary outcome [14] 461420 0
Neurodegeneration measure by neurofilament lightchain (NfL)
Timepoint [14] 461420 0
Baseline, 24 months post intervention
Secondary outcome [15] 461421 0
Astrogliosis measured by level of glial fibrillary acidic protein (GFAP)
Timepoint [15] 461421 0
Baseline and 24 months post intervention
Secondary outcome [16] 461457 0
General inflammation (c-reactive protein)
Timepoint [16] 461457 0
Baseline and 24 months post intervention

Eligibility
Key inclusion criteria
• 60 years of age or older
• Presence of subjective cognitive decline (SCD), defined as an ECog-12 score < 1.54, or cognitive performance consistent with mild cognitive impairment (MCI), defined by a T-MoCA score > 13/22 and < 19/22.
• Ability to read, write and communicate in English to a comfortable level
• At least one of the following risk factors: insufficient physical activity, poor diet or low levels of cognitive engagement
• Willingness to nominate a friend, family or carer who is willing to provide information about the participant’s memory and thinking and their everyday behaviour at the beginning and end of the study.
• Willingness to complete an online course, lifestyle factor questionnaires and interviews over phone/video call with ability to connect to the internet
• No current diagnosed psychiatric or neurological disorders (other than MCI)
Minimum age
60 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
• Clinician-confirmed or self-reported dementia
• Severe cognitive impairment, defined as an age- and education-adjusted T-MoCA score < 13 out of 22
• Currently participating in a similar healthy ageing intervention
• Medical or psychiatric conditions that would adversely impact participation in the trial.

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Participants who meet all inclusion criteria and none of the exclusion criteria will be invited to complete the Baseline assessment via video call, or by phone if video call is not feasible. After the Baseline assessment, participants will be randomly assigned to one of two groups using a pre-determined allocation sequence generated by an independent study statistician. Randomisation will be implemented through a centralised REDCap randomisation module to ensure allocation concealment. Participants will be informed of their group allocation by a member of the research team who is not involved in outcome assessment.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
The randomisation sequence will be created by a statistician who is independent of participant testing. Block randomisation will be generated using STATA, with a 1:1 allocation ratio. Stratification factors will include age (60–75 and 75+) and sex (male, female, another sex (Please specify); I prefer not to say).

Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Sample Size Calculation:
The primary outcome will be analysed using a linear mixed-effects model with random intercepts and fixed effects for intervention group (analysed on an intention-to-treat basis), time, and their interaction. Published data from lifestyle risk reduction trials on similar cognitive outcomes at 24 months suggest small effect sizes (0.13 to 0.40 standard deviations). Prior studies also indicate moderate effects on risk profiles (0.50 standard deviations) and on quality of life and mood, with attrition typically 1 to 2 percent per month (Anstey et al., 2015; Anstey et al., 2020; Chandler et al., 2019).
The required sample size is 788 participants, which provides 80 percent power to detect a target effect size of 0.1 standard deviations at a two-sided significance level of 5 percent, using a repeated-measures design in STATA. The assumed target effect for cognition (measured using the mNTB composite score) is the difference between intervention and control groups at 24 months relative to baseline, assuming a correlation of 0.65 between repeated measurements and total attrition of 30 percent.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
ACT,NSW,NT,QLD,SA,TAS,WA,VIC

Funding & Sponsors
Funding source category [1] 321060 0
Government body
Name [1] 321060 0
Department of Health and Aged Care, Dementia Ageing and Aged Care Mission, Medical Research Future Fund
Country [1] 321060 0
Australia
Primary sponsor type
University
Name
University of New South Wales
Address
Country
Australia
Secondary sponsor category [1] 323766 0
None
Name [1] 323766 0
Address [1] 323766 0
Country [1] 323766 0
Other collaborator category [1] 283840 0
University
Name [1] 283840 0
University of Melbourne
Address [1] 283840 0
Country [1] 283840 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319598 0
The University of New South Wales Research Ethics Committee A
Ethics committee address [1] 319598 0
Ethics committee country [1] 319598 0
Australia
Date submitted for ethics approval [1] 319598 0
05/12/2025
Approval date [1] 319598 0
23/03/2026
Ethics approval number [1] 319598 0
iRECS8670

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 147818 0
Prof Kaarin J. Anstey
Address 147818 0
Rm 1203 Matthews Building, University of New South Wales Sydney, Kensington, 2052, NSW
Country 147818 0
Australia
Phone 147818 0
+61 412935746
Fax 147818 0
Email 147818 0
Contact person for public queries
Name 147819 0
Kaarin Anstey
Address 147819 0
Rm 1203 Matthews Building, University of New South Wales Sydney, Kensington, 2052 NSW
Country 147819 0
Australia
Phone 147819 0
+61 412935746
Fax 147819 0
Email 147819 0
Contact person for scientific queries
Name 147820 0
Kaarin Anstey
Address 147820 0
School of Psychology, Matthews Building, UNSW, Kensington, NSW, 2052, Sydney
Country 147820 0
Australia
Phone 147820 0
+61 412935746
Fax 147820 0
Email 147820 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
• Requires a scientifically sound proposal or protocol
• Requires approval by an ethics committee
• Requires a data sharing agreement between data requester and trial custodian or sponsor
What individual participant data might be shared?
• De-identified individual participant data:
• All outcomes data
• Published results
• Primary outcome(s)
What types of analyses could be done with individual participant data?
• Systematic reviews and meta-analyses
• Health economic analyses
• Studies testing whether findings can be repeated or confirmed
When can requests for individual participant data be made (start and end dates)?
From:
Approximately mid 2032, after publication of main outcome paper.

To:
Not yet decided
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: [email protected]

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.